Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540395 | 1.00 | CYP24A1 (1.00) | CYP24A1CYP27B1 | |
| SCHEMBL1503385 | 1.00 | CYP24A1 (1.00) | CYP24A1CYP27B1 | |
| SCHEMBL7126449 | 0.97 | CYP24A1 (0.94) | CYP24A1CYP27B1 | |
| SCHEMBL7070181 | 0.87 | CYP24A1 (0.77) | CYP24A1CYP27B1 | |
| SCHEMBL7068187 | 0.83 | CYP24A1 (0.70) | CYP24A1CYP27B1 | |
| SCHEMBL7066367 | 0.82 | CYP24A1 (0.69) | CYP24A1CYP27B1 | |
| SCHEMBL28508110 | 0.81 | CYP24A1 (0.72) | CYP24A1CYP27B1 | |
| SCHEMBL7068036 | 0.79 | CYP24A1 (0.74) | CYP24A1CYP27B1 | |
| SCHEMBL7071390 | 0.79 | CYP24A1 (0.74) | CYP24A1CYP27B1 | |
| SCHEMBL7072584 | 0.79 | CYP24A1 (0.74) | CYP24A1CYP27B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2281058-B1 | METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS | OPKO IRELAND GLOBAL HOLDINGS LTD (IE) | 2016-06-29 | — | — | EP | claimed |
| CN-1060163-C | Acylated aminoalknimidazoles and-triazoles | NORVATIS (CH) | 2001-01-03 | — | — | CN | claimed |
| EP-0683156-B1 | Acylated aminoalkanimidazoles and -triazoles | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | claimed |
| US-5622982-A | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS | SANDOZ LTD. (CH) | 1997-04-22 | — | — | US | claimed |
| CN-1120039-A | Acylated aminoalknimidazoles and-triazoles | SANDOZ LTD (CH) | 1996-04-10 | — | — | CN | claimed |
| EP-0683156-A1 | Acylated aminoalkanimidazoles and -triazoles | SANDOZ LTD. (CH) | 1995-11-22 | — | — | EP | claimed |
| JP-8053422-A | — | — | None | — | — | JP | disclosed |
| US-10302660-B2 | Methods useful for vitamin D deficiency and related disorders | OPKO RENAL, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170067917-A1 | METHODS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS | EIRGEN PHARMA LTD. (IE) | 2017-03-09 | — | — | US | disclosed |
| EP-3112476-A2 | METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS | Opko Ireland Global Holdings, Ltd. (IE) | 2017-01-04 | — | — | EP | disclosed |
| US-9500661-B2 | Methods useful for vitamin D deficiency and related disorders | OPKO RENAL, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2281058-B1 | METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS | OPKO IRELAND GLOBAL HOLDINGS LTD (IE) | 2016-06-29 | — | — | EP | disclosed |
| US-20150141385-A1 | Methods Useful for Vitamin D Deficiency and Related Disorders | EIRGEN PHARMA LTD. (IE) | 2015-05-21 | — | — | US | disclosed |
| US-20090088373-A1 | USE OF COMPOSITIONS TO ENHANCE INNATE IMMUNE RESPONSE | BVR TECHNOLOGIES CO. | 2009-04-02 | — | — | US | disclosed |
| CN-1060163-C | Acylated aminoalknimidazoles and-triazoles | NORVATIS (CH) | 2001-01-03 | — | — | CN | disclosed |
| EP-0683156-B1 | Acylated aminoalkanimidazoles and -triazoles | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5622982-A | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS | SANDOZ LTD. (CH) | 1997-04-22 | — | — | US | disclosed |
| CN-1120039-A | Acylated aminoalknimidazoles and-triazoles | SANDOZ LTD (CH) | 1996-04-10 | — | — | CN | disclosed |
| JP-H0853422-A | ACYLATED AMINOALKANEIMIDAZOLES AND TRIAZOLES | SANDOZ AG | 1996-02-27 | — | — | JP | disclosed |
| EP-0683156-A1 | Acylated aminoalkanimidazoles and -triazoles | SANDOZ LTD. (CH) | 1995-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088373-A1 | USE OF COMPOSITIONS TO ENHANCE INNATE IMMUNE RESPONSE | MYD88, MTOR, TLR3 | CYP24A1 153/4885CYP27B1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.